Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Issued Date
2023-01-01
Resource Type
ISSN
14760584
eISSN
17448395
Scopus ID
2-s2.0-85142148414
Pubmed ID
36330971
Journal Title
Expert Review of Vaccines
Volume
22
Issue
1
Start Page
1
End Page
16
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Vaccines Vol.22 No.1 (2023) , 1-16
Suggested Citation
Solante R., Alvarez-Moreno C., Burhan E., Chariyalertsak S., Chiu N.C., Chuenkitmongkol S., Dung D.V., Hwang K.P., Ortiz Ibarra J., Kiertiburanakul S., Kulkarni P.S., Lee C., Lee P.I., Lobo R.C., Macias A., Nghia C.H., Ong-Lim A.L., Rodriguez-Morales A.J., Richtmann R., Safadi M.A.P., Satari H.I., Thwaites G. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Review of Vaccines Vol.22 No.1 (2023) , 1-16. 16. doi:10.1080/14760584.2023.2143347 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81525
Title
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Author's Affiliation
China Medical University Children's Hospital
Oxford University Clinical Research Unit
Fundación Universitaria Autónoma de las Américas
Pasteur Institute in Ho Chi Minh City
Universidad Cientifica del Sur
San Lazaro Hospital
University of the Philippines College of Medicine
University of Medicine and Pharmacy at HCMC
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Universitas Indonesia
Instituto de Infectologia Emilio Ribas
Universidad de Guanajuato
Mackay Memorial Hospital Taiwan
National Taiwan University College of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Nuffield Department of Medicine
Chiang Mai University
Taylor's School of Medicine
Philippine Children's Medical Centre
Hospital Materno Perinatal Mónica Pretelini Sáenz
Clinica Universitaria Colombia
Serum Institute of India Ltd.
Santa Casa de São Paulo School of Medical Sciences
National Vaccine Institute
Oxford University Clinical Research Unit
Fundación Universitaria Autónoma de las Américas
Pasteur Institute in Ho Chi Minh City
Universidad Cientifica del Sur
San Lazaro Hospital
University of the Philippines College of Medicine
University of Medicine and Pharmacy at HCMC
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Universitas Indonesia
Instituto de Infectologia Emilio Ribas
Universidad de Guanajuato
Mackay Memorial Hospital Taiwan
National Taiwan University College of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Nuffield Department of Medicine
Chiang Mai University
Taylor's School of Medicine
Philippine Children's Medical Centre
Hospital Materno Perinatal Mónica Pretelini Sáenz
Clinica Universitaria Colombia
Serum Institute of India Ltd.
Santa Casa de São Paulo School of Medical Sciences
National Vaccine Institute
Other Contributor(s)
Abstract
Introduction: COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Areas covered: Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently available COVID-19 vaccines. Expert opinion: Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that. The positive risk-benefit ratio of these vaccines is well established, giving us confidence to administer additional doses as required. Future vaccination strategies will likely include a combination of schedules based on risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population.